1. A systematic liquid biopsy program identifies novel and heterogeneous mechanisms of acquired resistance in gastrointestinal (GI) cancer patients. (December 2016) Authors: Parikh, A.; Kwak, E.; Goyal, L.; Blaszkowsky, L.; Hazar-Rethinam, M.; Siravegna, G.; Russo, M.; Van Seventer, E.; Nadres, B.; Shahzade, H.; Clark, J.; Allen, J.; Iafrate, A.J.; Bardellli, A.; Ryan, D.; Murphy, J.; Zhu, A.; Hong, T.; Corcoran, R. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Acquired resistance to selective FGFR inhibitors in FGFR-altered cholangiocarcinoma. (October 2020) Authors: Goyal, L.; Baiev, I.; Zhang, K.; Dalgai, S.; Shroff, R.T.; Kelley, R.K.; Uboha, N. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Hospital readmissions following percutaneous liver tumor ablation using the nationwide readmissions database. (March 2019) Authors: Qadan, M.; Molina, G.; Sell, N.M.; Ferrone, C.R.; Tanabe, K.K.; Elias, N.; Dageford, L.A.; Uppot, R.N.; Wo, J.Y.; Goyal, L. Journal: HPB Issue: Volume 21(2019)Supplement 1 Page Start: S181 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor. (October 2022) Authors: Schram, A.; Borad, M.; Sahai, V.; Kamath, S.; Kim, R.; Liao, C.Y.A.; Oh, D.Y.; Ponz-Sarvisé, M.; Yachnin, J.; Shell, S.A.; Cassier, P.; Dotan, E.; Florou, V.; Moreno, V.; Park, J.O.; Tai, D.; Schmidt-Kittler, O.; Ferté, C.; Goyal, L.; Subbiah, V. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S116 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. PO-1033 Molecular profile and early MRI changes after chemoradiation in high grade diffuse astrocytoma. (August 2021) Authors: Basu Achari, R.; Goyal, L.; Chakraborty, S.; Arunsingh, M.; Arun, B.; Das, S.; Bhattacharyya, T.; Mallick, I.; Chatterjee, S.; Chatterjee, J.; Dhara, S.; Ghosh, N.; Mukhopadhyay, J. Journal: Radiotherapy and oncology Issue: Volume 161(2021)supplement Page Start: S862 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Treatment of Cholangiocarcinoma with a Humanized Anti-Claudin-1 Monoclonal Antibody. (October 2022) Authors: Muller, M.; Nehme, Z.; Röhlen, N.; Juehling, F.; Crouchet, E.; Pessaux, P.; Felli, E.; Goyal, L.; Meyer, M.; Iacone, R.; Toso, A.; Bardeesy, N.; Schuster, C.; Mailly, L.; Baumert, T. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S93 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗